Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | PTAFR | P25105 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.32 |
| ▸ | LTA4H | P09960 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6977314 | 0.99 | GABRA1 (0.36) | GABRA1GABRA5FPR1FPR2TBXAS1 | |
| Sulfuric Acid SCHEMBL6983443 | 0.97 | GABRA1 (0.35) | GABRA1GABRA5FPR1FPR2TBXAS1 | |
| SCHEMBL7668963 | 0.97 | GABRA1 (0.36) | GABRA1GABRA5FPR1FPR2TBXAS1 | |
| SCHEMBL7084093 | 0.95 | MCL1 (0.35) | GABRA1GABRA5FPR1FPR2TBXAS1 | |
| Nitric Acid SCHEMBL6981278 | 0.95 | CYP19A1 (0.35) | GABRA1GABRA5FPR1FPR2TBXAS1 | |
| Maleic Acid SCHEMBL6982359 | 0.94 | TBXAS1 (0.34) | GABRA1GABRA5FPR1FPR2TBXAS1 | |
| Fumaric Acid SCHEMBL6982366 | 0.94 | TBXAS1 (0.34) | GABRA1GABRA5FPR1FPR2TBXAS1 | |
| SCHEMBL6978829 | 0.93 | GABRA1 (0.36) | GABRA1GABRA5FPR1FPR2TBXAS1 | |
| SCHEMBL7671370 | 0.92 | GABRA1 (0.34) | GABRA1GABRA5FPR1FPR2TBXAS1 | |
| SCHEMBL7671373 | 0.92 | GABRA1 (0.34) | GABRA1GABRA5FPR1FPR2TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179152-A1 | Novel use for PDE5 inhibitors | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-1740183-B1 | NOVEL USE FOR PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2009-10-14 | — | — | EP | claimed |
| US-20070185114-A1 | Novel use for pde5 inhibitors | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| EP-1461022-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA Pharma AG (DE) | 2004-09-29 | — | — | EP | claimed |
| WO-2003051346-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | claimed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | claimed |
| EP-3267986-B1 | PDE5 INHIBITORS FOR USE IN REDUCING RENAL CYST SIZE AND/OR PREVENTING RENAL CYST GROWTH | UNIV INDIANA RES & TECH CORP (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-107847462-B | Targeting cGMP-related phosphodiesterases to reduce cyst formation of cystic kidney disease and related materials and methods | 美国印第安纳大学研究和技术公司 | 2021-08-10 | — | — | CN | disclosed |
| US-10456404-B2 | Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180078559-A1 | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY COPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| EP-3267986-A1 | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS | Indiana University Research&Technology Corporation (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016149218-A1 | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-09-22 | — | — | WO | disclosed |
| US-8329656-B2 | Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders | SWITCH BIOTECH AG (DE) | 2012-12-11 | — | — | US | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1136072-A1 | PREPARATIONS FOR INTRAURETHRAL ADMINISTRATION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
| US-6197768-B1 | THERAPY, PREVENTION ISCHEMIC HEART DISEASE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0985671-A1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-6018046-A | SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |